Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection

被引:32
作者
Menne, Stephan [1 ]
Butler, Scott D. [1 ]
George, Andrea L. [1 ]
Tochkov, Ilia A. [1 ]
Zhu, Yuao [2 ]
Xiong, Shelly [2 ]
Gerin, John L. [3 ]
Cote, Paul J. [3 ]
Tennant, Bud C. [1 ]
机构
[1] Cornell Univ, Gastrointestinal Unit, Dept Clin Sci, Coll Vet Med, Ithaca, NY 14853 USA
[2] Gilead Sci Inc, Durham, NC 27707 USA
[3] Georgetown Univ, Med Ctr, Dept Microbiol & Immunol, Washington, DC 20057 USA
关键词
D O I
10.1128/AAC.00654-08
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Adefovir dipivoxil (ADV) and tenofovir disoproxil fumarate (TDF) are nucleotide analogs that inhibit the replication of wild-type hepatitis B virus (HBV) and lamivudine (3TC)-resistant virus in HBV-infected patients, including those who are coinfected with human immunodeficiency virus. The combination of ADV or TDF with other nucleoside analogs is a proposed strategy for managing antiviral drug resistance during the treatment of chronic HBV infection. The antiviral effect of oral ADV or TDF, alone or in combination with 3TC or emtricitabine (FTC), against chronic woodchuck hepatitis virus (WHV) infection was evaluated in a placebo-controlled study in the woodchuck, an established and predictive model for antiviral therapy. Once-daily treatment for 48 weeks with ADV plus 3TC or TDF plus FTC significantly reduced serum WHV viremia levels from the pretreatment level by 6.2 log(10) and 6.1 log(10) genome equivalents/ml serum, respectively, followed by TDF plus 3TC (5.6 log(10) genome equivalents/ml), ADV alone (4.8 log(10) genome equivalents/ml), ADV plus FTC (one survivor) (4.4 log(10) genome equivalents/ml), TDF alone (2.9 log(10) genome equivalents/ml), 3TC alone (2.7 log(10) genome equivalents/ml), and FTC alone (2.0 log(10) genome equivalents/ml). Individual woodchucks across all treatment groups also demonstrated pronounced declines in serum WHV surface antigen, characteristically accompanied by declines in hepatic WHV replication and the hepatic expression of WHV antigens. Most woodchucks had prompt recrudescence of WHV replication after drug withdrawal, but individual woodchucks across treatment groups had sustained effects. No signs of toxicity were observed for any of the drugs or drug combinations administered. In conclusion, the oral administration of 3TC, FTC, ADV, and TDF alone and in combination was safe and effective in the woodchuck model of HBV infection.
引用
收藏
页码:3617 / 3632
页数:16
相关论文
共 71 条
[51]   Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: Final long-term results [J].
Schiff, Eugene ;
Lai, Ching-Lung ;
Hadziyannis, Stephanos ;
Neuhaus, Peter ;
Terrault, Norah ;
Colombo, Massimo ;
Tillmann, Hans ;
Samuel, Didier ;
Zeuzem, Stefan ;
Villeneuve, Jean-Pierre ;
Arterburn, Sarah ;
Borroto-Esoda, Katyna ;
Brosgart, Carol ;
Chuck, Steven ;
Shakil, Ahmad Obaid ;
Fung, John ;
Alberti, Alfredo ;
Lok, Anna ;
Picciotto, Antonio ;
Torre, Francesco ;
Riely, Caroline ;
Trepo, Christian ;
Bizollon, Thierry ;
Botta-Fridlund, Danielle ;
Gerolami, Rene ;
Douglas, David ;
Ranjan, Dinesh ;
Faust, Dominik ;
Trojan, Joerg ;
Gane, Edward ;
Villa, Erica ;
Boarino, Valentina ;
Sokal, Etienne ;
Starkel, Peter ;
Bonino, Ferruccio ;
Brunetto, Maurizia ;
Gordon, Fred ;
Pratt, JoAnne ;
Berr, Frieder ;
Schiefke, Ingolf ;
McCaughan, Geoff ;
Strasser, Simone ;
Dusheiko, Geoffrey ;
Pageaux, Georges Philipp ;
Larrey, Dominique ;
Pastore, Giuseppe ;
Santantonio, Teresa ;
Alexander, Graeme ;
Woodall, Tracy ;
Van Vlierberghe, Hans .
LIVER TRANSPLANTATION, 2007, 13 (03) :349-360
[52]   Effects of pyrimidine and purine analog combinations in the duck hepatitis B virus infection model [J].
Seignères, B ;
Martin, P ;
Werle, B ;
Schorr, O ;
Jamard, C ;
Rimsky, L ;
Trépo, C ;
Zoulim, F .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (06) :1842-1852
[53]   Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B [J].
Sung, Joseph J. Y. ;
Lai, Jak-Yiu ;
Zeuzem, Stefan ;
Chow, Wan Chen ;
Heathcote, E. Jenny ;
Perrillo, Robert P. ;
Brosgart, Carol. L. ;
Woessner, Mary A. ;
Scott, Susan A. ;
Gray, D. Fraser ;
Gardner, Stephen D. .
JOURNAL OF HEPATOLOGY, 2008, 48 (05) :728-735
[54]   Tenofovir monotherapy is effective in hepatitis B patients with antiviral treatment failure to adefovir in the absence of adefovir-resistant mutations [J].
Tan, Jessica ;
Degertekin, Bulent ;
Wong, Stephen N. ;
Husain, Munira ;
Oberhelman, Kelly ;
Lok, Anna S. F. .
JOURNAL OF HEPATOLOGY, 2008, 48 (03) :391-398
[55]   Mutations in the conserved woodchuck hepatitis virus polymerase FLLA and YMDD regions conferring resistance to lamivudine [J].
Tatti, KM ;
Korba, BE ;
Stang, HL ;
Peek, S ;
Gerin, JL ;
Tennant, BC ;
Schinazi, RF .
ANTIVIRAL RESEARCH, 2002, 55 (01) :141-150
[56]   Hepatocellular carcinoma in the woodchuck mode of hepatitis B virus infection [J].
Tennant, BC ;
Toshkov, IA ;
Peek, SF ;
Jacob, JR ;
Menne, S ;
Hornbuckle, WE ;
Schinazi, RD ;
Korba, BE ;
Cote, PJ ;
Gerin, JL .
GASTROENTEROLOGY, 2004, 127 (05) :S283-S293
[57]   Antiviral activity and toxicity of fialuridine in the woodchuck model of hepatitis B virus infection [J].
Tennant, BC ;
Baldwin, BH ;
Graham, LA ;
Ascenzi, MA ;
Hornbuckle, WE ;
Rowland, PH ;
Tochkov, IA ;
Yeager, AE ;
Erb, HN ;
Colacino, JM ;
Lopez, C ;
Engelhardt, JA ;
Bowsher, RR ;
Richardson, FC ;
Lewis, W ;
Cote, PJ ;
Korba, BE ;
Gerin, JL .
HEPATOLOGY, 1998, 28 (01) :179-191
[58]  
TENNANT BC, 1999, CLIN LIVER DIS, V3, P241
[59]   Treatment of recurrent hepatitis B infection in liver transplant recipients [J].
Terrault, NA .
LIVER TRANSPLANTATION, 2002, 8 (10) :S74-S81
[60]   Hepatitis B virus (HBV) mutations associated with resistance to lamivudine in patients coinfected with HBV and human immunodeficiency virus [J].
Thibault, V ;
Benhamou, Y ;
Seguret, C ;
Bochet, M ;
Katlama, C ;
Bricaire, F ;
Opolon, P ;
Poynard, T ;
Agut, H .
JOURNAL OF CLINICAL MICROBIOLOGY, 1999, 37 (09) :3013-3016